Antitrypanosomal activities of fluoroquinolones with pyrrolidinyl substitutions

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 9, 2003, Pages 3015-3017

  Nenortas, Elizabeth ^a   Kulikowicz, Tomasz ^a   Burri, Christian ^a,b   Shapiro, Theresa A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 7 (3 AMINO 1 PYRROLIDINYL) 1 CYCLOPROPYL 6,8 DIFLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; 7 (3 AMINO 1 PYRROLIDINYL) 1 CYCLOPROPYL 6,8 DIFLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; ANTITRYPANOSOMAL AGENT; CARBON; CIPROFLOXACIN; CLINAFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); OFLOXACIN; PD 114980; PD 120755; PD 120978; PD 124979; PD 125023; PD 131199; PD 134914; PD 143891; PYRROLIDINE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; THIAZOLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL LINE; DNA PROTEIN COMPLEX; DRUG EFFECT; DRUG STRUCTURE; ENZYME INHIBITION; NONHUMAN; NUCLEIC ACID SYNTHESIS; PRIORITY JOURNAL; TRYPANOSOMA BRUCEI;

ANIMALS; ANTI-INFECTIVE AGENTS; DNA; DNA TOPOISOMERASES, TYPE I; FLUOROQUINOLONES; LEUKEMIA L1210; MICE; PYRROLIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE; TRYPANOCIDAL AGENTS; TRYPANOSOMA; TRYPANOSOMA BRUCEI BRUCEI; TUMOR CELLS, CULTURED;

EID: 0041421172     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.9.3015-3017.2003     Document Type: Article

References (12)

1. Bodley, A. L., M. W. McGarry, and T. A. Shapiro. 1995. Drug cytotoxicity assay for African trypanosomes and Leishmania species. J. Infect. Dis. 172:1157-1159.
2. Bodley, A. L., and T. A. Shapiro. 1995. Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. Proc. Natl. Acad. Sci. USA 92:3726-3730.
3. Bodley, A. L., M. C. Wani, M. E. Wall, and T. A. Shapiro. 1995. Antitrypanosomal activity of camptothecin analogs. Structure-activity correlations. Biochem. Pharmacol. 50:937-942.
4. Burri, C. A., A. L. Bodley, and T. A. Shapiro. 1996. Topoisomerases in kinetoplastids. Parasitol. Today 12:226-231.
5. Keiser, J., and C. Burri. 2001. Evaluation of quinolone derivatives for antitrypanosomal activity. Trop. Med. Int. Health 6:369-389.
6. Legros, D., G. Ollivier, M. Gastellu-Etchegorry, C. Paquet, C. Burri, J. Jannin, and P. Buscher. 2002. Treatment of human African trypanosomiasis - present situation and needs for research and development. Lancet Infect. Dis. 2:437-440.
7. Nenortas, E., C. Burri, and T. A. Shapiro. 1999. Antitrypanosomal activity of fluoroquinolones. Antimicrob. Agents Chemother. 43:2066-2068.
8. Shapiro, T. A. 1993. Inhibition of topoisomerases in African trypanosomes. Acta Trop. 54:251-260.
9. Shapiro, T. A., and P. I. Englund. 1990. Selective cleavage of kinetoplast DNA minicircles promoted by antitrypanosomal drugs. Proc. Natl. Acad. Sci. USA 87:950-954.
10. Shapiro, T. A., V. A. Klein, and P. T. Englund. 1989. Drug-promoted cleavage of kinetoplast DNA minicircles. Evidence for type II topoisomerase activity in trypanosome mitochondria. J. Biol. Chem. 264:4173-4178.
11. Smith, D. H., J. Pepin, and A. H. Stich. 1998. Human African trypanosomiasis: an emerging public health crisis. Br. Med. Bull. 54:341-355.
12. Stich, A., P. M. Abel, and S. Krishna. 2002. Human African trypanosomiasis. BMJ 325:203-206.